Sepsis refers to life-threatening organ dysfunction associated with infection. It is a leading cause of acute kidney injury (AKI) in patients with critical illness, and 60% of patients with sepsis present with AKI (Poston & Koyner, 2019;Skube et al., 2018). Injected lipopolysaccharide (LPS), a major component of the outer membrane of gram-negative bacteria, can induce sepsis and mimic the infection observed in humans (Kupferschmid et al., 2018). Following LPS injection, renal tubular epithelial cells express toll-like receptor 4 (TLR4), and the binding of the LPS to TLR4 activates the downstream signaling pathways, including the nuclear factor-κB (NF-κB) pathway; this activation triggers an inflammatory response involving increased synthesis of proinflammatory cytokines and reactive oxygen species (ROS) as well as oxidative stress, ultimately leading to multiple-organ dysfunction (Liu & Malik, 2006;(Peerapornratana et al., 2019)). However, adenosine monophosphate-activated protein kinase (AMPK) can suppress inflammation, inhibit NF-κB signaling (Salt & Palmer, 2012), and promote the activation of the antioxidant nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase (HO)-1 pathway against oxidative stress (Lei et al., 2020;Zimmermann et al., 2015).